Indefinite Delivery Contract 75D30122D12995
Award Date
1/5/22
Last Date to Order
2/28/23
Federal Agency
CDC Pittsburgh
Awardee
Astrazeneca Pharmaceuticals LP
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
This indefinite delivery contract was awarded by the Centers for Disease Control and Prevention (CDC) to Astrazeneca Pharmaceuticals LP, a foreign-owned, for-profit pharmaceutical manufacturer. The $47.2 million, multiple-award contract, with a period of performance through February 2021, is for the procurement of pediatric influenza vaccines. Astrazeneca is a leading global biopharmaceutical company that has supplied various pharmaceutical products, medical treatments, and medical...
This indefinite delivery contract was awarded by the Centers for Disease Control and Prevention (CDC), a civilian agency within the Department of Health and Human Services (HHS), to AstraZeneca Pharmaceuticals LP, a foreign-owned, for-profit pharmaceutical manufacturer. The contract, valued at $377,600,000.00, is for the procurement of influenza vaccines to support adult and pediatric immunization programs. AstraZeneca, a leading global biopharmaceutical company, has a history of providing...
This indefinite delivery contract was awarded by the Centers for Disease Control and Prevention (CDC) to AstraZeneca Pharmaceuticals LP, a foreign-owned pharmaceutical manufacturer, on December 31, 2024. The contract has a ceiling value of $51,900,000 and a period of performance through February 28, 2026. The primary purpose of this IDV is to procure pediatric influenza vaccines for the 2025-2026 season. AstraZeneca, as the prime contractor, will provide these vaccines to the CDC and potentially...
This indefinite delivery contract was awarded by the Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh to provide pediatric flu vaccines for 2023-2024. Astrazeneca Pharmaceuticals LP is the prime contractor for this multiple-award contract with a potential value of $58.53M. The contract aims to procure pediatric flu vaccines through a series of task orders against an established price list. As the lead federal agency for public health emergency...
This Indefinite Delivery Contract (IDC) was awarded by the U.S. Centers for Disease Control and Prevention (CDC), a civilian federal agency, to AstraZeneca Pharmaceuticals LP, a foreign-owned, for-profit pharmaceutical manufacturer. The contract ceiling value is $15,136,570.80 with a period of performance through February 28, 2025. The purpose of this IDC is to procure pediatric influenza vaccines for the 2024-2025 timeframe. AstraZeneca, a leading global biopharmaceutical company, has a history...
The Centers for Disease Control and Prevention (CDC) awarded a single award Indefinite Delivery Contract to Glaxosmithkline, LLC, a pharmaceutical company, to procure pediatric influenza vaccines for the 2022-2023 season. The contract has a potential value of $168,590,000 and a period of performance from the date of award through February 28, 2023. The original solicitation sought between 100 doses and 50 million doses of pediatric influenza vaccine to be delivered to CDC distribution centers in...
The Centers for Disease Control and Prevention awarded a single award indefinite delivery contract to Seqirus USA Inc. with a potential value of $180,705,000. The contract aims to procure pediatric influenza vaccines for children ages 0 through 18 years old to support immunization programs under Section 317(j) of the Public Health Service Act and the Vaccines for Children program. Task orders will be issued against the contract to purchase required vaccines each flu season through February 28,...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), a civilian agency within the Department of Health and Human Services, to AstraZeneca Pharmaceuticals LP, a foreign-owned for-profit pharmaceutical manufacturer. The $131,584,000 contract is for the delivery of influenza vaccines for adult immunization programs under Section 317(j) of the Public Health Service Act. There was no set-aside used for this single-award IDC, which has a period...
This Indefinite Delivery Contract (IDC) is a multiple-award vehicle awarded by the Centers for Disease Control and Prevention (CDC), a civilian federal agency under the Department of Health and Human Services, to AstraZeneca Pharmaceuticals LP, a foreign-owned, for-profit pharmaceutical manufacturer. The contract has a ceiling value of $8,820,000.00 and a period of performance through February 28, 2025, for the procurement of adult influenza vaccines during the 2024-2025 flu season....
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) to AstraZeneca Pharmaceuticals LP for the procurement of adult influenza vaccines for the 2022-2023 flu season. The contract has a ceiling value of $12,337,500.00 and a period of performance from the date of award on January 5, 2022 through February 28, 2023. The contract aims to procure a minimum of 100 doses and a maximum...